The business strategy of Barkan Pharma is based on the continued clinical development of the drug Raviset ® for marketing approval in Western countries (FDA or the equivalent European authorities).

 

Simultaneously BARKAN PHARMA ISRAEL is developing the markets in Eastern European and other countries in the Far East.

 

The company has already started to operate in the markets that do not require FDA approval.

 

Raviset® is already registered in Moldova, as a treatment for pain & Excessive bleeding during

menstrual period.

 

The Barkan Pharma Israel marketing plan includes the distribution of the drug in Eastern Europe and especially in Ukraine, Russia, Kazakhstan, Belorussia and Uzbekistan. The company also aims to penetrate the Chinese market.

 

The Company's objective is to focus on the development of its drug for pain & Excessive bleeding during menstrual period and to shortly conduct a Phase II clinical trial in the US under FDA guide lines. The preliminary clinical trials conducted in Moldova resulted in approved and confirmed clinical data, demonstrating that Rviset® exhibits a robust safety profile and is highly effective in the treatment

of pain & Excessive bleeding during menstrual period.

 

The successful completion of this first milestone will present the investors with an attractive exit point with an anticipated company valuation of approximately 100 million dollars. Barkan Pharma is confident that this milestone can be achieved within 24 months.